You are here

A Virtual Experience

Vertical Tabs

Vertical Tabs

Register for Virtual Poster Session
58 Confirmed Posters

List of Confirmed Posters

2020 Poster Session: A Virtual Experience
Date of CE Release:  August 25, 2020
Date of CE Expiration:  January 31, 2021
Location: Online


1 Transcranial Magnetic Stimulation for Neuropathic Pain- An INS/NANS Expert Consensus Panel Review and Recommendation Albert Leung
2 Repetitive Transcranial Magnetic Stimulation (rTMS): A Large-Scale Retrospective Clinical Data Analysis Indicating rTMS as Effective Treatment for Generalized Anxiety Disorder (GAD) Alex Engelbertson
3 Case Study: Preliminary Results of Hypnosis in Conjunction with rTMS for Comorbid Anxiety and Depression Alice Musher
4 Neuronavigation Guided rTMS in Alleviating Gulf War Illness Symptoms Alphonsa Kunnel
6 Anhedonia in Major Depressive Disorder: Can it be the Chicken And the Egg for Transcranial Magnetic Stimulation? Andrew M. Fukuda
7 Initial report on long-term durability of deep TMS for obsessive compulsive disorder Aron Tendler
8 Preliminary characteristic of 45 patient of the study placebo-controlled, randomized, double-blind clinical trial to assess the safety and efficacy of using Deep Transcranial Magnetic Stimulation (EMTp) in smoking cessation Bianca Boura Bellini
10 Post Marketing Rate of Seizures During Transcranial Magnetic Stimulation (TMS) Treatment with NeuroStar Advanced Therapy Is Low Karen Heart
11 Transcranial Magnetic Stimulation Induces Insomnia; A Case Series Christina Raghunandan
12 Elderly TMS Response and Duration: A 6 Month Study Debra J. Stultz
13 Gender Related TMS Response in Depression and Insomnia Debra J. Stultz
14 A novel Theta Burst Transcranial Magnetic Stimulation (θTMS) protocol to decrease suicidal ideation Mark Xuereb
15 Audio-Guided Mindfulness Meditation During TMS Sessions for the Treatment of Major Depressive Disorder (MDD): A Feasibility Pilot Study Eric Tirrell
16 Outcomes of Ketamine IV Treatments for TMS Therapy Poor Responders Erin Amato
17 Does it Matter if Depressed Patients get TMS Sessions Less Often than 5 Times per Week? A Treatment Schedule Density Analysis Fatih Kokdere
18 Gender Differences in Transcranial Magnetic Stimulation Treatment Outcomes for Major Depressive Disorder: A Single Institution E Ganesh Maniam
19 Real-world efficacy of deep TMS for obsessive-compulsive disorder: interim post-marketing analysis of 192 patients from twenty-two sites Geoffrey Grammer
20 Incidence of side effects in patients receiving Repetitive Transcranial Magnetic Stimulation (rTMS) Harpreet Singh
21 Music and rTMS; Novel combination approach for the treatment of depression Irakli Mania
22 A Study of Bilateral Prefrontal rTMS to Treat the Symptoms of mTBI and PTSD: Preliminary Effectiveness and Tolerability Megan Tsui
23 Two Cycles of rTMS as a Protective Measure Against Early-Onset Alzheimer’s Disease: A Case Report Megan Tsui
25 A systematic review and meta-analysis comparing iTBS to rTMS to sham in randomized controlled trials Jeffrey Voigt
26 Repetitive Transcranial Magnetic Stimulation and migraine: Case Report José Ricardo López Melgar
29 The Efficacy of rTMS with Psychotherapy, Sleep Modifications & Exercise Karan Narwal
31 Therapeutic Efficacy of Off-label TMS Protocol for Posttraumatic Stress Disorder: A Case Study Kimi Hashimoto
32 Bipolar Depressed Patients Respond Better to rTMS Than Unipolar Depressed Patients Larissa Gama-Chonlon
33 Low Frequency (1Hz) dTMS H1 Coil over the Right DLPFC for Late Life TRD: Case Report Lucian Manu
34 Transcranial Magnetic Stimulation for Persistent Post-Traumatic Headache- An INS/NANS Expert Consensus Panel Recommendation Maheen M. Adamson
35 Psychiatric comorbidities did not influence remission and response rates in patients treated with transcranial magnetic stimulation Malik Nassan
36 Repetitive Transcranial Magnetic Stimulation (rTMS) of spinal cord for freezing of gait in Parkinson disease: A Pilot Study Marco Antonio Marcolin
37 Use of Transcranial Magnetic stimulation in treatment resistant depression in MU health care: Effectiveness and outcome Meelie Bordoloi
39 Cortical pain modulatory functional enhancement after rTMS associated with durable headache improvement in mTBI patients Michael Vaninetti
40 The effects of extended rTMS treatment course on response outcome in patients with Major Depressive Disorder - Salience 51 Naima Monira
41 Evaluation of cognitive performance in clinically depressed patients using THINC-it after rTMS treatment Naima Monira
42 MDD Responds Equally to dTMS With and Without Comorbid Personality Disorders Owen Muir
43 Accelerated and Non-Accelerated dTMS Protocols Both Effective in Treatment of MDD Owen Muir
44 TMS Treatment With the H1 Coil in Youth Age 10-21 Effective in Ameliorating MDD Symptoms Owen Muir
47 A Review of Non-Invasive Brain Stimulation for Cognitive Impairment: Evidence for Expansion of Clinical Indications Pranav Jagtap
48 Case Study: Treatment of Pediatric OCD with rTMS Priya Parmar
49 A retrospective outcome study comparing the effectiveness of rTMS therapy provided 3 versus 5 treatments per week. Randy Pardell
50 Bilateral rTMS Shows No Advantage in Depression nor in Comorbid Depression and Anxiety: A Large Naturalistic Study Rebecca Mae Allen
51 Cost-Effectiveness of TMS in Managing Neuropathic Pain (NP) and Co-Morbid Depression Richard A. Bermudes
52 Outcomes of Standard TMS Treatment Compared to Theta Burst Protocol for MDD in a Naturalistic Setting Rick Trautner 
Derek Schumm
53 What is the durability of deep TMS for major depressive disorder? Roman Gersner 
54 Cognitive Training During TMS Does Not Improve Depression Outcomes Sandeep Vaishnavi
55 A Cognitive Biomarker May Optimize TMS Depression Outcomes Sandeep Vaishnavi
60 Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospe Steve Best
61 Deep TMS for major depression, interim post-marketing analysis of 1040 patients Steven A. Harvey
62 Safety of TMS Treatment up to 140% of Motor Threshold Todd Hutton
63 Comparison of Naturalistic Treatment Outcomes with the Standard 38-Minute Protocol vs. Shortened (“Dash”) Protocol: A NeuroStar® W. Scott West
64 Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment Resistant Depression (SAINT-TRD): results from a double-blinded, randomized, and controlled trial Angela Leah Phillips
65 Theta Burst Compared to Standard Repetitive Transcranial Magnetic Stimulation For Major Depressive Disorder At A Suburban Tertiary Clinic Amelia Hess
66 Effectiveness of multiple rTMS treatments per day for Depressive Disorder at Living Mind, UK Arghya Sarkhel
68 Transcranial Magnetic Stimulation for Neuropathic Pain: Treating Comorbid Pain and Depression Joshua Kuluva
69 Increased Absolute Power in the Left Prefrontal Cortex with TMS Treatment For Complex Depression Laura Viner
70 Outcomes and feasibility from the first TMS specific web-based intervention Michelle Cochran
71 Clinical Outcomes using dTMS targeting the DMPFC-ACC in Treatment-Resistant OCD Richard A. Bermudes
72 The Case for Incorporating EEG in Clinical TMS Practice Shelly Menolascino

Acknowledgment of Financial and/or In-Kind Commercial Support
No financial or in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must review each poster chosen and take up to 15 minutes to absorb the information and complete an evaluation form to receive a certificate of completion.

Complete all posters you wish to view before completing the evaluation.

If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.  


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Clinical TMS Society.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 14.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Objectives - After Attending This Program You Should Be Able To

  1. Identify evidence for various TMS treatment approaches compared to standard TMS approach
  2. Discuss the effectiveness of TMS in various populations and settings
  3. Discuss predictive biomarkers and/or clinical markers of response to repetitive transcranial magnetic stimulation (rTMS) treatment

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed on the website. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

First Name

Last Name

Commercial Interest: Relationship



Janssen: Consultant, Neuronetics: Research Grant Overall Principal Investigator, Affect Neuro: Consultant, Neosync: Research Grant Site Principal Investigator, Affect Neuro: Research Grant Overall Principal Investigator, Janssen: Research Grant Site Principal Investigator, Nexstim: Research Equipment Loan, Neuronetics: Research Equipment Loan, Neuronetics: Consultant, Sage Therapeutics: Consultant, Neurolief: Consultant



BrainsWay: Employee*



Greenbrook TMS: Scientific/Medical Advisory Board Member, Greenbrook TMS: Employee, Neuronetics: Stock Shareholder, Brainsway: Research Grant Site Principal Investigator



Eli Lilly: Employee*



Neuronetics: Employee*



Sunovion: Speakers Bureau



Sunovion: Speakers Bureau



Brainsway: Research Funding, speaker



Neuronetics:Speakers Bureau



Neuronetics: Other



Jazz Pharmaceticuls: Speakers Bureau, Harmony Biosciences: Speakers Bureau



Brainsway Ltd.: Consultant, Advanced Mental Health Care: Stock Shareholder, Aron Tendler MD PA: Stock Shareholder, Brainsway Ltd.: Stock Shareholder



Magstim: Consultant

* Employee relationships with commercial interest organizations were vetted and found to be unbiased.

TOP 6 Webinar Recordings

TOP 6 Flash Poster Presentations

Webinar Recordings
TOP 6 Flash Poster Presentations Overview

Since 2018, CTMSS has provided a speaking platform for the Top 4 Poster Abstracts at the Annual Meeting. We are thrilled to be able to continue to share our top research and findings.

The Abstract Review Committee decided to include an additional two abstracts this year to be presented since the 2020 Annual Meeting in Chicago was regrettably canceled. These abstracts were originally scheduled as general presentations for the conference and as such, were not eligible for being selected to present during this session. Thus, this year there was a total of 6 top abstracts presented. 

Moderated by Andy Kozel, MD, CTMSS Research Chair

Dr. Kozel is the Director of the TMS Clinic and Staff Psychiatrist in Mental Health and Behavioral Sciences (MH&BS) at the James A. Haley Veteran's Hospital; as well as Professor, Department of Psychiatry and Behavioral Sciences, University of South Florida. Dr. Kozel's work with neuromodulation techniques like TMS has included research, clinical care, teaching, and dissemination for over 20 years. His research uses brain imaging and brain stimulation to better understand and treat neuropsychiatric disorders with the focus of improving the lives of patients with these disorders.

Anhedonia in Major Depressive Disorder: Can it be the Chicken and the Egg for Transcranial Magnetic Stimulation?

Anhedonia is a severely debilitating hallmark feature of Major Depressive Disorder (MDD) and a symptom which is often difficult to treat. Snaith-Hamilton Pleasure Scale (SHAPS), a validated 14-question self-assessment for anhedonia, was collected in a naturalistic setting before and after TMS for treatment-resistant MDD. TMS resulted in a significant improvement in hedonic drive from pre to post TMS overall. Patients whose MDD met response criteria had a significantly greater degree of improvement in hedonic drive. However, baseline anhedonia severity was not a predictor of TMS clinical response.

Presented by Andrew M. Fukuda, MD, PhD

Dr. Fukuda is a 3rd year General Psychiatry Resident at Brown University and is also part of the NIMH R25-funded research track. He earned his MD and Ph.D. from Loma Linda University in California through the Medical Scientist Training Program. He has been engaged in TMS research under the mentorship of Dr. Linda Carpenter since starting residency.

Does it Matter if Depressed Patients get TMS Sessions Less Often than 5 Times per Week? A Treatment Schedule Density Analysis

TMS therapy for Major Depressive Disorder (MDD) was administered on a strictly-enforced schedule of 5 sessions per week for the first 4-6 weeks. In real-life clinical practice, circumstances that prevent adherence to this session schedule occasionally arise. This current retrospective study explores whether deviations from this “optimal” TMS treatment schedule impact final depression clinical outcomes in a naturalistic treatment setting.

Presented by Fatih Kokdere, MD

Dr. Kokdere is currently a psychiatry resident at MercyOne Medical Center in Des Moines, Iowa. He has worked as a research scholar at Butler Hospital TMS Clinic and Neuromodulation Research Facility under the supervision of Dr. Linda Carpenter after completing his medical education in Istanbul, Turkey.

Systematic Review and Meta-Analysis Comparing iTBS vs. TMS vs. Sham in Randomized Controlled Trials

Intermittent theta-burst stimulation (iTBS) is being used more frequently for the treatment of major depressive disorder. It has advantages, including a shorter duration of therapy. The objective was to evaluate the outcomes (response and safety/adverse events) of intermittent theta-burst stimulation (iTBS) to repetitive transcranial magnetic stimulation (rTMS) and to sham (iTBS v. sham) when used in patients with major depressive disorder (MDD) in randomized controlled trials (RCTs). The Cochrane methodology was used to evaluate the effect of iTBS in MDD. Results demonstrated a statistically significant improvement in the response of iTBS vs. sham; no statistical difference in this outcome when iTBS was compared to rTMS and; no statistical difference in adverse events when compared to sham. iTBS should be considered as a treatment alternative to rTMS in MDD.

A video recording for Abstract #25 is unavailable. Click here to check out the PDF abstract or register to view the poster at the CTMSS 2020 Virtual Poster Session and reach out directly to the author.

Author: Jeffrey D. Voigt, MBA, MPH

Jeff Voigt is an expert in the field of evidence assessments and cost-effectiveness analysis having published over 30 papers on these subjects in various peer-reviewed journals. Jeff is also an Associate Editor of Cost Effectiveness and Resource Allocation. Jeff resides and works in northern New Jersey.

Evaluation of Cognitive Performance in Clinically Depressed Patients Using THINC-it® After rTMS Treatment

This naturalistic, clinical study evaluated the cognitive performance of 265 patients primarily diagnosed with MDD, using THINC-it® Cognitive Screener.  Patients completed five daily treatments for 7-8 weeks (approx.. 36 total treatments) over the right dorsolateral prefrontal cortex (dlPFC) at 1 Hz for 360 pulses followed by left dlPFC stimulation at 20 Hz for 1200 pulses.  57.36% of patients achieved remission (≥ 70% improvement on PHQ-9) and significant moderate effect was found after rTMS in overall performance on the Choice Reaction Time Identification Task (d = -.38, p < .001) and Trail Making Test-Part B (d = -.39, p < .001). Cognitive performance after TMS suggests patients’ executive function, working memory, processing speed, and attention may have improved.

Presented by Naima Monira, MS

Naima Monira is a Clinical Analyst at Salience TMS Neuro Solutions. She obtained her B.A. in Psychology at Baylor University and both, her Masters in Human Development & Early Childhood Disorders and Applied Cognition & Neuroscience from the University of Texas at Dallas. In the past, Naima worked as a research clinician at the Center for BrainHealth at the University of Texas at Dallas and as a curriculum consultant at Hanson Robokind.

A Multicenter, Randomized, Sham-Controlled Trial of Left Prefrontal, 10 Hz, Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression

The objective of this study was to examine the feasibility, safety, and efficacy of 10 Hz repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder in adolescents. Based on the largest study of adolescents to date, Left prefrontal 10 Hz rTMS monotherapy appears to be feasible, tolerable, and safe in adolescents with treatment-resistant depression. Future studies should focus on study designs to reduce placebo response rates, larger sample size, and dose-finding approaches for adolescents with depression.

Presented by Paul E. Croarkin, DO, MS

Dr. Croarkin’s research program focuses on adapting and innovating brain stimulation interventions in children and adolescents. This includes biomarker work to optimize diagnostic practices and the delivery of brain-based interventions such as transcranial magnetic stimulation.  A central theme focuses on the role of gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems in early-onset mood disorders with the goal of informing safer and more effective biologic treatments. Dr. Croarkin is a professor of psychiatry in the Mayo Clinic College of Medicine and the Director of the Mayo Clinic Depression Center.

Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT-TRD) Induces Rapid remission from Treatment-Resistant Depression in a Double-Blinded, Randomized, and Controlled Trial

Major depressive disorder (MDD) is the leading cause of disability worldwide and half of patients have treatment-resistant depression (TRD). Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for TRD but is limited by suboptimal efficacy and 6-week treatment duration. We addressed this by developing Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), which was associated with a ~90% remission rate after 5 days of treatment in an open-label study. Herein, we report the results of a sham-controlled, double-blinded trial of SAINT for TRD.

Presented by Angela Leah Phillips, PhD, LICSW

Angela currently has a dual postdoctoral role with the Stanford Brain Stimulation Lab, and the VA, Palo Alto, CA, USA. She obtained her BA from the University of North Carolina in Clinical Psychology, followed by her MSW and clinical licensure in Mental Health Practice, and PhD in Nursing Science, from the University of Washington. Angela has worked across inpatient and outpatient clinical psychiatry for over a decade with research interests focusing on neuromodulatory psychiatric and mental health interventions, including novel non-invasive brain stimulation methods, and combined psychotherapeutic interventions for complex neurological and neuropsychiatric disorders.